Johannes Gutenberg-Universität Mainz
- 6131/39-0
Niemann, Bernd; Stoppe, Christian; Wittenberg, Michael et al.
Rational and Initiative of the Impella in Cardiac Surgery (ImCarS) Register Platform (Jul, 10.1055/s-0042-1749686, 2021)THORACIC AND CARDIOVASCULAR SURGEON. 2022
Hess, Connie N.; Capell, Warren H.; Bristow, Michael R. et al.
Rationale and design of a study to assess the safety and efficacy of rNAPc2 in COVID-19: the Phase 2b ASPEN-COVID-19 trialAMERICAN HEART JOURNAL. Bd. 246. 2022 S. 136-143
Junger, Claus; Prochaska, Jurgen H.; Gori, Tommaso et al.
Rationale and design of the effects of EMpagliflozin on left ventricular DIAstolic function in diabetes (EmDia) studyJOURNAL OF CARDIOVASCULAR MEDICINE. Bd. 23. H. 3. 2022 S. 191-197
Thiem, Corina E.; Stegmann, Jil D.; Hilger, Alina C. et al.
Re-sequencing of candidate genes FOXF1, HSPA6, HAAO, and KYNU in 522 individuals with VATER/VACTERL, VACTER/VACTERL-like association, and isolated anorectal malformationBIRTH DEFECTS RESEARCH. Bd. 114. H. 10. 2022 S. 478-486
Graf, Christiana; Dietz, Julia; Muellhaupt, Beat et al.
REAL-LIFE EFFECTIVENESS OF VOXILAPREVIR/VELPATASVIR/SOFOSBUVIR IN HEPATITIS C PATIENTS PREVIOUSLY TREATED WITH DIRECT-ACTING ANTIVIRAL AGENTS (DAA)HEPATOLOGY. Bd. 76. 2022 S. S48-S49
Antony, James W.; Ngo, Hong-Viet V.; Bergmann, Til Ole et al.
Real-time, closed-loop, or open-loop stimulation? Navigating a terminological jungleJOURNAL OF SLEEP RESEARCH. Bd. 31. H. 6. 2022
Welland, Sabrina; Leyh, Catherine; Finkelmeier, Fabian et al.
Real-World Data for Lenvatinib in Hepatocellular Carcinoma (ELEVATOR): A Retrospective Multicenter StudyLIVER CANCER. Bd. 11. H. 3. 2022 S. 219-232
Stoelzl, Dora; Sander, Nicole; Heratizadeh, Annice et al.
Real-world data on the effectiveness, safety and drug survival of dupilumab: an analysis from the TREATgermany registryBRITISH JOURNAL OF DERMATOLOGY. Bd. 187. H. 6. 2022 S. 1022-1024
Lueftner, Diana; Brucker, Cosima; Decker, Thomas et al.
Real-world efficacy of ribociclib (RIB) plus aromatase inhibitor (AI)/fulvestrant (FUL), or endocrine monotherapy (ET), or chemotherapy (CT) as first-line (1L) treatment (tx) in patients (pts) with hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC): Results of fourth interim analysis (IA) from RIBANNA.JOURNAL OF CLINICAL ONCOLOGY. Bd. 40. H. 16. 2022
Luftner, Diana; Brucker, Cosima; Decker, Thomas et al.
Real-world efficacy of ribociclib plus aromatase inhibitor/fulvestrant, or endocrine monotherapy, or chemotherapy as first-line treatment in women with hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) locally advanced or metastatic breast cancer: Fourth interim analysis from the RIBANNA studyCANCER RESEARCH. Bd. 82. H. 4. 2022